Results 51 to 60 of about 60,513 (321)

PATHOMORPHOLOGICAL ANALYSIS OF TREPANOBIOPTATES IN CHRONIC MYELOID LEUKEMIA AND CHRONIC LYMPHOCYTIC LEUKEMIA: ASSESSMENT OF THE PROGNOSTIC VALUE OF MYELOFIBROSIS WHEN COMPARED WITH CLINICAL DATA

Сибирский научный медицинский журнал, 2019
The aim of the study was to study the relationship between the qualitative and quantitative characteristics of myelofibrosis and the clinical manifestations of chronic myeloid leukemia and chronic lymphocytic leukemia. Material and methods.
T. Y. Dolgikh, E. V. Vinogradova, V. I. Kapustina, S. R. Senchukova   +3 more
doaj   +1 more source

Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure

American journal of hematology/oncology, 2020
Fedratinib is an oral, selective Janus kinase 2 (JAK2) inhibitor. The phase II JAKARTA2 study assessed fedratinib in patients with intermediate‐ or high‐risk myelofibrosis (MF) who were resistant or intolerant to prior ruxolitinib per investigator ...
C. Harrison, N. Schaap, A. Vannucchi, J. Kiladjian, E. Jourdan, R. Silver, H. Schouten, F. Passamonti, S. Zweegman, M. Talpaz, S. Verstovsek, S. Rose, Juan Shen, T. Berry, C. Brownstein, R. Mesa   +15 more
semanticscholar   +1 more source

Adding hydroxyurea in combination with ruxolitinib improves clinical responses in hyperproliferative forms of myelofibrosis [PDF]

, 2019
Ruxolitinib, an orally bioavailable and selective inhibitor of Janus kinase 1 (JAK1) and JAK2, significantly reduces splenomegaly and disease-related symptoms in patients with myelofibrosis (MF).
Annunziata, M., Casale, B., Cerchione, C., Crisa, E., Giordano, C., Grimaldi, F., Iovine, M., Luciano, L., Martinelli, V., Nappi, D., Pane, F., Pezzullo, L., Picardi, M., Pugliese, N., Villa, M. R.   +14 more
core   +1 more source

Splenic pooling and loss of VCAM-1 causes an engraftment defect in patients with myelofibrosis after allogeneic hematopoietic stem cell transplantation

Haematologica, 2016
Myelofibrosis is a myeloproliferative neoplasm that results in cytopenia, bone marrow fibrosis and extramedullary hematopoiesis. Allogeneic hematopoietic stem cell transplantation is the only curative treatment but is associated with a risk of delayed ...
Christina Hart, Sabine Klatt, Johann Barop, Gunnar Müller, Roland Schelker, Ernst Holler, Elisabeth Huber, Wolfgang Herr, Jochen Grassinger   +8 more
doaj   +1 more source

Primary Myelofibrosis with Mesenteric Extramedullary Haematopoiesis [PDF]

Journal of Clinical and Diagnostic Research, 2018
Primary myelofibrosis or chronic idiopathic myelofibrosis is a myeloproliferative neoplasm characterized by proliferation of abnormal haematopoietic stem cells in bone marrow resulting in replacement of marrow with fibrotic scar tissue.
Saurabh Kumar, Shaloo Shaloo, Juhi Chawla, Subha Ashok, Shalini Thapar Laroia   +4 more
doaj   +1 more source

Case Report: Effects of Secondary Hyperparathyroidism Treatment on Improvement of Juvenile Nephronophthisis-Induced Pancytopenia and Myelofibrosis

Frontiers in Pediatrics, 2021
Secondary hyperparathyroidism (HPT) is a common complication of end-stage renal disease (ESRD) and may be an important precipitating factor for the development of myelofibrosis.
Keishiro Amano, Hidemi Toyoda, Kouhei Nishikawa, Tomohiro Murata, Masahiro Hirayama   +4 more
doaj   +1 more source

Disseminated tuberculosis with myelofibrosis presentation: a case report

Journal of Medical Case Reports, 2021
Background Primary myelofibrosis is a rare myeloproliferative disorder in middle-aged and old adults and should be distinguished from secondary and reactive causes of bone marrow fibrosis because, in reactive fibrosis, treatment approaches depend on the ...
Mahdi Khatuni, Marziyeh Ghalamkari, Fereshteh Ameli, Habibeh Yekehtaz   +3 more
doaj   +1 more source

Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia

Haematologica, 2021
Thrombocytopenia is common in patients with myelofibrosis (MF) and is a well-established adverse prognostic factor. Both of the approved Janus kinase (JAK) inhibitors, ruxolitinib and fedratinib, can worsen thrombocytopenia and have not been evaluated in
S. Verstovsek, R. Mesa, M. Talpaz, J. Kiladjian, C. Harrison, S. Oh, A. Vannucchi, R. Rampal, B. Scott, S. Buckley, A. Craig, K. Roman‐Torres, J. Mascarenhas   +12 more
semanticscholar   +1 more source

Targeted Therapy of Myelofibrosis [PDF]

Клиническая онкогематология, 2017
Background. Myelofibrosis (primary myelofibrosis, post-essential trombocythemia myelofibrosis, post-polycythemia myelofibrosis) is the most complex and pressing problem among all Ph-negative myeloproliferative diseases. The present article summarizes the
OYu Vinogradova, VA Shuvaev, IS Martynkevich, MM Pankrashkina, MS Fominykh, EV Efremova, KYu Krutikova, LB Polushkina, NN Sharkunov, SV Voloshin, AV Chechetkin   +10 more
doaj   +1 more source

Case Report: Hematologic Recovery Following Stereotactic Ablative Radiotherapy in a Patient With Early-Stage Non-Small Cell Lung Cancer and Paraneoplastic Myelofibrosis

Frontiers in Oncology, 2022
Herein, we report the first case presentation of paraneoplastic myelofibrosis associated with cancer. Paraneoplastic syndromes occur in some patients with thoracic malignancies; however, myelofibrosis is not commonly seen in non-small cell lung cancer ...
Lindsey Sloan, Lindsey Sloan, Rakhi P. Naik, Kavita Umrau, Rena Ruiyu Xian, Kristen A. Marrone, Khinh Ranh Voong   +6 more
doaj   +1 more source